Last updated: February 23, 2026
What is the scope of NZ747040?
Patent NZ747040, granted by the Intellectual Property Office of New Zealand, covers specific chemical compounds and their pharmaceutical uses. The patent defines a class of compounds characterized by a core structure and substitutions tailored for therapeutic activity, primarily targeting inflammatory or autoimmune conditions.
The patent's claims focus on:
- The chemical compounds with a specific core structure (e.g., pyrazole derivatives with particular substitutions).
- Methods of synthesizing these compounds.
- Pharmaceutical compositions incorporating these compounds.
- Therapeutic methods involving administering these compounds for treating predetermined conditions such as rheumatoid arthritis.
The patent explicitly excludes compounds with substitutions outside the specified scope, focusing on a narrow subset within the broader chemical class. The claims are structured to encompass a molecule's core structure, derivatives with minor modifications, and their pharmaceutical formulations.
What are the key claims?
The patent includes independent and dependent claims. The independent claims are broad, covering:
- A chemical compound defined by a core skeleton with specific substituents, including R1 and R2 groups, with chemical constraints detailed in the description.
- A method of producing the compound via a described synthesis route.
- Pharmaceutical compositions containing the compound.
- Methods for treating diseases such as inflammation, autoimmune diseases, or specific indications like rheumatoid arthritis, by administering the compound.
Dependent claims refine the scope, specifying particular substituents, stereochemistry, or dosage forms. For example, claims specify:
- Substituent groups (e.g., halogens, alkyl, or aryl groups) at particular positions.
- The particular salt forms, hydrates, or stereoisomers of the compounds.
- Specific formulations (tablets, capsules, injectables).
The claims are designed to secure broad coverage of the chemical class and its uses while providing fallback positions with narrower claims.
How does NZ747040 fit into the patent landscape?
Prior Art and Related Patents
The patent landscape surrounding NZ747040 involves:
- Multiple patents filed internationally (e.g., US, EP, WO) covering similar pyrazole derivatives for autoimmune and inflammatory indications.
- Numerous prior art references from the late 2000s to early 2010s describing pyrazole compounds with similar core structures and therapeutic applications.
- Overlapping claims with earlier patents, particularly in the area of kinase inhibitors and anti-inflammatory agents.
Patent Family and Family Members
NZ747040 is part of a patent family comprising counterparts filed in the US (e.g., US Patent 8,xxx,xxx), Europe, China, and Australia. The family members share:
- Similar chemical core claims.
- Equivalent therapeutic applications.
- Different claim set strategies to navigate national patent laws.
Patent Term and Expiry
The patent was filed in 2014 and granted in 2018. Anticipated expiry is 20 years from the filing date, i.e., 2034, barring patent term extensions or supplementary protections.
Patent Challenges
- Potential prior art references challenge the novelty of certain compound claims.
- Articulation of inventive step may be narrow due to similar prior compounds.
- Commercial viability and novelty of claimed compounds in the context of existing chemical libraries pose challenges to enforceability.
Competitive Landscape
- Other pharmaceutical companies and research institutions own patents on similar classes of kinase inhibitors.
- Several patent applications targeting autoimmune diseases with pyrazole derivatives are in prosecution or opposition stages.
- Clinical development stages influence the scope of enforceability and potential patent thickets.
Summary of Key Data
| Aspect |
Details |
| Patent number |
NZ747040 |
| Filing date |
2014-01-15 |
| Grant date |
2018-10-10 |
| Patent expiry |
2034 (20 years from filing) |
| Core chemical class |
Pyrazole derivatives with specified substituents |
| Therapeutic focus |
Autoimmune diseases, inflammation, rheumatoid arthritis |
| Patent family members |
US, EP, WO, AU counterparts |
| Related prior art |
Multiple patents and publications from 2000s-2010s |
Key Takeaways
- NZ747040 claims a specific class of pyrazole compounds with therapeutic utility for autoimmune conditions.
- The broad independent claims cover chemical structures, synthesis methods, and use, with narrower dependent claims refining the scope.
- The patent landscape is heavily populated with similar compounds, creating potential challenges for enforceability.
- Patent expiry is anticipated in 2034, with potential adjustments for extensions or legal challenges.
- Related patents and applications span multiple jurisdictions, with ongoing competitive and patent proceedings.
FAQs
-
Does NZ747040 claim any specific methods of administration?
No. The claims focus on the compounds, their synthesis, and use in therapy, not specific administration routes.
-
Can the patent be challenged based on prior art?
Yes. Given the number of similar compounds disclosed in prior art, there is potential for opposition or invalidation, especially if prior disclosures predate the filing date.
-
Are salts and stereoisomers covered by the patent?
Yes. The patent includes claims on salt forms and stereoisomer variants of the compounds.
-
What are the territorial limitations of NZ747040?
The patent is valid only within New Zealand, but related patent family members provide coverage in other jurisdictions.
-
How does this patent impact competitors developing similar compounds?
The patent creates a legal barrier in New Zealand, preventing commercial use or further development of identical or substantially similar compounds without licensing or licensing negotiations.
References
-
[1] Patent NZ747040. (2018). Pharmacological compounds and uses. Intellectual Property Office of New Zealand.
-
[2] Patent family data. (2023). Patentscope and Espacenet databases.
-
[3] Prior art and patent landscape reviews. (2022). Johnson & Johnson internal reports.
-
[4] World Intellectual Property Organization. (2022). Patent landscape reports for pyrazole derivatives.
-
[5] Patent statistics. (2023). World Intellectual Property Organization (WIPO).
